Malignant Hypertension:A Systemic Cardiovascular Disease: JACC Review Topic of the Week.
(2024) Journal of the american college of cardiology : JACC — Vol. 83, n° 17, p. 1688-1701 (2024)
Files
2024_Boulestreau_J_Am_Coll_Cardiol.pdf
Open Access - Adobe PDF
- 3.21 MB
Details
- Authors
- Abstract
- Malignant hypertension (MHT) is a hypertensive emergency with excessive blood pressure (BP) elevation and accelerated disease progression. MHT is characterized by acute microvascular damage and autoregulation failure affecting the retina, brain, heart, kidney, and vascular tree. BP must be lowered within hours to mitigate patient risk. Both absolute BP levels and the pace of BP rise determine risk of target-organ damage. Nonadherence to the antihypertensive regimen remains the most common cause for MHT, although antiangiogenic and immunosuppressant therapy can also trigger hypertensive emergencies. Depending on the clinical presentation, parenteral or oral therapy can be used to initiate BP lowering. Evidence-based outcome data are spotty or lacking in MHT. With effective treatment, the prognosis for MHT has improved; however, patients remain at high risk of adverse cardiovascular and kidney outcomes. In this review, we summarize current viewpoints on the epidemiology, pathogenesis, and management of MHT; highlight research gaps; and propose strategies to improve outcomes.
- Affiliations
Citations
Boulestreau, R., Śpiewak, M., Januszewicz, A., Kreutz, R., Guzik, T. J., Januszewicz, M., Muiesan, M. L., Persu, A., Sarafidis, P., Volpe, M., Zaleska-Żmijewska, A., van den Born, B.-J. H., & Messerli, F. H. (2024). Malignant Hypertension:A Systemic Cardiovascular Disease: JACC Review Topic of the Week. Journal of the american college of cardiology : JACC, 83(17), 1688-1701. https://doi.org/10.1016/j.jacc.2024.02.037 (Original work published 2024)